Legis
Healthcare
Public law · Tuesday 3 November 2026
Public law 119-138
H.R. 8205

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

The law extends federal ALS therapy access and research programs through fiscal year 2031 and strengthens grant oversight.

Listen to the summary
0:00

It sustains support for therapies targeting ALS and other rare neurodegenerative diseases while requiring closer review of drug safety, effectiveness, and trial progress.

What the law does ​

  • Reauthorizes federal ALS therapy access and research programs through fiscal year 2031.
  • Requires grant-renewal reviews to assess available enrollment, safety, and effectiveness data for investigational drugs.
  • Requires applicants to promptly report new, serious, and unexpected adverse events and other phase 3 trial safety information to the grant-making institution.
  • Allows combined phase 2/3 trials to qualify as phase 3 trials when enrollment begins within the grant’s required timeframe.
  • Directs the Food and Drug Administration to publish a five-year rare neurodegenerative disease action plan within 18 months and report on its actions and results within five years.

Who it affects ​

  • People with ALS and other rare neurodegenerative diseases.
  • Researchers, clinical trial sponsors, and federal grant applicants.
  • Institutions awarding federal ALS research grants.

Breakdown ​

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 ​

This law extends federal programs supporting access to and research on therapies for ALS and other rare neurodegenerative diseases through fiscal year 2031. It strengthens review and safety-reporting requirements for ALS research grants and requires the Food and Drug Administration to publish and later report on a five-year action plan.

Key takeaways

  • Federal ALS therapy and research programs are reauthorized through fiscal year 2031.
  • When reviewing an ALS research grant renewal, the federal government must request and assess available enrollment, safety, and effectiveness data for the investigational drug.
  • Grant applicants must promptly report new, serious, and unexpected adverse events and safety information related to the phase 3 trial to the grant-making institution.
  • A combined phase 2/3 clinical trial may qualify as a phase 3 trial if enrollment begins within a timeframe set in the grant conditions.
  • The FDA must publish a five-year rare neurodegenerative disease action plan within 18 months after enactment.
  • The FDA must publish a report within five years after enactment describing its actions under the plan and how well the plan met the law’s requirements.